The tweet was deleted by the author.
But we saved everything 🙂.
UroGen Pharma will report its second quarter 2026 financial results during a live webcast on Wednesday, August 5 at 10:00 AM ET.
Details on how to access the webcast are available in the company's announcement. The stock trades under the symbol URGN.
View post on X Loading...
URGN is currently trading at $40.88, above the MA-20 ($39.81), MA-50 ($34.07), and MA-200 ($24.74), which confirms a bullish structure for the short, medium, and long-term trends. The Ichimoku Kijun level on D1 stands at $38.82, placing immediate support below the current price. Near-term support lies at the MA-20 ($39.81) and Ichimoku Kijun ($38.82), while key support is next at the MA-50 ($34.07). Resistance is seen first at the MA-5 cluster ($41.57) and then at MA-10 ($41.28) as near-term levels, with the previous 52-week high ($43.93) serving as key resistance.
Momentum indicators on D1 show strong underlying bullishness, with MACD signaling a strong buy and ADX at a high reading of 42.90, both indicating a persistent upward trend. RSI at 61.11 and CCI at 56.11 suggest moderate bullish territory, while Stoch RSI flags an oversold condition, adding some divergence to the outlook. BBP indicates overbought conditions with continued buyer pressure. The Awesome Oscillator is neutral and does not provide a clear confirmation of the prevailing trend. URGN is trading at $40.88, little changed from last week’s close of $40.97, reflecting a marginal decline of 0.22%. The price sits in the lower part of the weekly range, with volatility for the week at 9.13%. This points to a period of consolidation after a pullback from recent highs.
Looking ahead, the expected price range for the next week is $39.75 to $44.00, keeping within a 10% band around the current price. Anchored between the 52-week low of $15.86 and the 52-week high of $43.93, this keeps URGN trading near the top end of its yearly range. W1 readings on MA-50, RSI, ADX, and MACD all give a "Buy" signal, resulting in a very high probability (more than 80%) of an upward move, with a low probability of reversal. The baseline scenario sees URGN consolidating between $39.75 and $44.00. A bullish scenario may see a breakout above $44.00, potentially targeting a new yearly high. The bearish scenario would emerge on a drop below $39.75, opening up downside risk toward the $38.80–$39.00 support area.
In a recent review, UroGen Pharma was characterized by analysts as maintaining a strong bullish bias, though with the possibility of short-term consolidation. With evolving market sentiment, traders should focus on monitoring emerging support levels to identify shifts in the prevailing trend direction.